kabutan

RIBOMIC Inc.(4591) Summary

4591
TSE Growth
RIBOMIC Inc.
95
JPY
-6
(-5.94%)
Mar 13, 3:30 pm JST
0.59
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
96
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.60
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
99 JPY 0.62 USD
Previous Close Mar 12
101 JPY 0.63 USD
High Mar 13, 9:00 am
99 JPY 0.62 USD
Low Mar 13, 9:00 am
94 JPY 0.58 USD
Volume
2,697,000
Trading Value
0.26B JPY 1.62M USD
VWAP
95.74 JPY 0.6 USD
Minimum Trading Value
9,500 JPY 59 USD
Market Cap
5.16B JPY 0.03B USD
Number of Trades
571
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
426
1-Year High Mar 3, 2026
9,798
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 21,900 7,861,700 358.98
Feb 27, 2026 0 7,297,600
Feb 20, 2026 0 7,548,300
Feb 13, 2026 0 7,912,400
Feb 6, 2026 0 8,254,200
Company Profile
RIBOMIC Inc. is a drug discovery venture originating from the University of Tokyo. The company develops molecular targeted drugs utilizing RNA and collaborates with major pharmaceutical companies.
Sector
Pharmaceuticals
RIBOMIC Inc. is a biotech venture company specializing in the development of aptamer drugs (molecular targeted therapies) originating from the University of Tokyo. The company conducts innovative research and development of aptamer drugs using its proprietary "RiboART System" technology platform. Its main pipeline includes the clinical development of umedaptanib pegol for age-related macular degeneration and achondroplasia. RIBOMIC is also developing multiple aptamer drug candidates for conditions such as pulmonary arterial hypertension and proliferative vitreoretinopathy. In the ophthalmology field, the company has a joint research agreement with the University of Tokyo. Additionally, through collaborations with pharmaceutical companies and in-house drug discovery efforts, RIBOMIC aims to create treatments for diseases with high unmet medical needs.